TEST:

BluePrint

Thermodynamic and electrochemical evaluation indicated greater stability and electron flow in co-culture reactors (R9:ΔG = -42.29 kJ) compared to monocultures. Collectively, this study presents a scalable hybrid bioelectrochemical strategy leveraging species-specific metabolic roles and electron-steering to facilitate high-yield, selective SA production, offering a promising blueprint for sustainable carbon-based biomanufacturing.

MMP, particularly its selected Mueller matrix elements, combined with clinical biomarkers show promise in distinguishing LBCS as validated against BluePrint®. By detecting subtle differences in tissue morphology, this approach may enhance breast cancer prognosis and help guide treatment decisions.

P=N/A, N=44, Completed, Stryker Trauma and Extremities | Recruiting --> Completed

Our results provide critical references for the efficacy and biomarkers of de-escalated neoadjuvant therapy in HER2-positive breast cancer. National Natural Science Foundation of China and Natural Science Foundation of Jiangsu Province.

"Agendia®, Inc...today announced the presentation of four major abstracts in collaboration with independent investigators at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29th– June 3rd, 2025, in Chicago, Illinois. "

Our study confirms that patients treated with SLN do not show a higher risk of LRNR compared to ALND. LRNR is often diagnosed incidentally. Younger age, residual disease post-NAC, no regional radiation, stage II, and initial LN involvement were more represented, as well as patients with endocrine sensitive disease classified as low-risk luminal A by MB. Ongoing trials, including SOUND, INSEMA, and BOOG 2013-08, are further exploring axillary surgery de-escalation.

This study identified gene expression signatures associated with breast cancer risk and molecular subtypes. These findings provide insights into the biological processes that may drive breast cancer progression and could inform the development of prognostic biomarkers and personalized therapeutic strategies.

Here, we review the published data on the most common gene expression signatures (MammaPrint (MP), BluePrint (BP), Oncotype Dx, PAM50, the Breast Cancer Index (BCI), and EndoPredict (EP)) and their ability to predict the response to neoadjuvant treatment, as well as the possibility of using them on core needle biopsies. Additionally, we review the changes in the gene expression signatures after neoadjuvant treatment, and the ongoing clinical trials related to the utility of gene expression signatures in the neoadjuvant setting.

P=Obs | N=3,0000 | FLEX (NCT03053193) | Sponsor: Agendia | "Agendia, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO Breast Cancer 2025 congress taking place May 14-17 in both Munich, Germany and virtually....The analysis found that patients with MammaPrint High Risk, HR+ HER2- Basal-type tumors were more likely to achieve a pCR following neoadjuvant chemotherapy compared to those with Luminal B tumors. The analysis also showed that these Basal-type tumors were more frequently recommended for chemotherapy overall, more often treated with neoadjuvant chemotherapy specifically, and received more intensive regimens compared to Luminal B tumors."

"Agendia®, Inc., announced today that new MammaPrint and BluePrint data and their ability to inform axillary surgery decisions in the neoadjuvant setting will be presented at the 26th American Society of Breast Surgeons Annual Meeting (ASBrS), taking place in Las Vegas, NV, April 30 – May 4, 2025. "

P2, N=39, Active, not recruiting, The Methodist Hospital Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Dec 2025

We treated the patient with a TNBC protocol, incorporating carboplatin and immunotherapy into the anthracycline-based chemotherapy backbone in the neoadjuvant setting. The patient achieved a complete response and remains to be disease-free after 2 years, with ongoing follow-up.